Scholl Verruca Removal System
国: マルタ
言語: 英語
ソース: Medicines Authority
情報リーフレット 有効成分:
SALICYLIC ACID
から入手可能:
Scholl Consumer Products Limited 103 - 105 Bath Road Slough, SL1 3UK, United Kingdom
ATCコード:
D11AF
INN（国際名）:
SALICYLIC ACID 40 % (W/W)
医薬品形態:
MEDICATED PLASTER
構図:
SALICYLIC ACID 40 % (W/W)
処方タイプ:
OTC
治療領域:
OTHER DERMATOLOGICAL PREPARATIONS
認証ステータス:
Suspended
承認日:
2006-08-29
情報リーフレット
LEAFLET
完全なドキュメントを読む
製品の特徴
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1.
TRADE NAME OF MEDICINAL PRODUCT
Scholl Verruca Removal System
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Salicylic Acid
40.0% w/w
3. PHARMACEUTICAL
FORM
Plaster
4. CLINICAL
PARTICULARS
4.1 THERAPEUTIC
INDICATIONS
For the treatment of common warts on the feet and hands.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Adults and Children
Select a medicated disc from those supplied which best fits the
size of the wart.
Leave medicated disc in place on wart for 48 hours and repeat
treatment.
Continue treatment for up to twelve weeks if necessary.
No distinction is made between age groups.
Neonates
Neonates should not be treated.
4.3 CONTRAINDICATIONS
a)
Not to be used by diabetics
or those with severe circulatory disorders, except following
a doctors permission and recommendation.
b)
Not to be used if the skin around the wart is inflamed or broken.
c)
Not to be used on moles, birthmarks, warts with hair growing
from them, genital warts
or warts on the face or mucous membranes.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
a)
Discontinue use and remove dressing if excessive
discomfort or irritation is
experienced.
b)
Do not apply to normal skin.
c)
For external use only.
Page 2 of 4
4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS
OF INTERACTION
Not relevant to cutaneous use.
4.6 PREGNANCY AND LACTATION
Safety during pregnancy and lactation has not been established.
4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
None stated.
4.8 UNDESIRABLE
EFFECTS
Local irritation may occur.
4.9 OVERDOSE
None stated.
5. PHARMACOLOGICAL
PROPERTIES
5.1 PHARMACODYNAMIC
PROPERTIES
Pharmacotherapeutic group
Keratolytics
Mechanism of Action
The mechani
完全なドキュメントを読む
